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Regulatory Domain Selectivity in the Cell-Type Specific
PKN-Dependence of Cell Migration
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Abstract
The mammalian protein kinase N (PKN) family of Serine/Threonine kinases comprises three isoforms, which are targets for
Rho family GTPases. Small GTPases are major regulators of the cellular cytoskeleton, generating interest in the role(s) of
specific PKN isoforms in processes such as cell migration and invasion. It has been reported that PKN3 is required for
prostate tumour cell invasion but not PKN1 or 2. Here we employ a cell model, the 5637 bladder tumour cell line where
PKN2 is relatively highly expressed, to assess the potential redundancy of these isoforms in migratory responses. It is
established that PKN2 has a critical role in the migration and invasion of these cells. Furthermore, using a PKN wild-type and
chimera rescue strategy, it is shown that PKN isoforms are not simply redundant in supporting migration, but appear to be
linked through isoform specific regulatory domain properties to selective upstream signals. It is concluded that intervention
in PKNs may need to be directed at multiple isoforms to be effective in different cell types.
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Introduction
Cell migration is a highly coordinated and tightly regulated
process engaging not only cytoskeletal remodelling events at the
front and rear of the cell, but also signalling cascades that translate
cues in the extracellular environment to determine the polarity of
the cell and the direction of movement. Small GTPases of the Rho
family are known for their roles in (re)organizing the cytoskeleton
(recently reviewed [1]) and in the generation of force important in
movement [2]. These actions are exerted through one or more of a
number of Rho family effectors (reviewed [3]). These effectors
embrace a variety of proteins including scaffolds, cytoskeleton
interacting proteins, protein kinases, lipid kinases, phospholipases
and oxidases and amongst these is the protein kinase C-related
family of serine/threonine protein kinases (PKN1-3).
The PKN family is closely related to the PKC family in their
conserved catalytic domains while differing in their N-terminal
regulatory domains. The three known isoforms, PKN1, 2 and 3
are closely related, exhibiting greatest variation within their
regulatory domains. All 3 isoforms contain three polybasic coiled-
coiled motifs the first two of which as elucidated for PKN1 and 2,
bind to Rac- and Rho GTPases [4,5,6,7]. Furthermore, the very
C-termini of PKN1 and 2 also play a role in binding to RhoA
[8,9]. In addition, PKN1 responds to phosphoinositides [10] and
fatty acids such as arachidonic, linoleic and oleic acid [11,12,13];
these properties differ for PKN2 [14]. The individual isoforms can
be activated upon specific growth factor receptor signalling such as
the androgen receptor for PKN1 [15,16], PDGF and CD44 for
PKN2 [17] and insulin for PKN3 [18]. It is therefore not
surprising that each isoform has been associated with different
adaptor proteins [19,20,21], suggesting that PKN isoforms may
not functionally substitute for one another, consistent with
apparently selective effects of isoforms.
One explanation for the observed PKN isoform specific effects
might in part be a consequence of the varying expression levels of
the PKNs. While the expression of PKN1 in human tissue
([11,22]) and PKN2 in mouse tissue [20] is rather ubiquitous, the
expression of PKN3 mRNA is relatively restricted to specific
tissues including skeletal muscle, heart and liver [22]. PKN3 was
found to be upregulated in various tumour cell lines [14], and
PKN1 overexpression has been correlated with tumour grade in
prostate cancer [16]. PKN3, but not PKN1 or PKN2, was shown
to play a role in invasion of a 3D matrix in PC3 cells [18]. This
may reflect the relative abundance of PKN3 in PC3 cells or may
suggest a unique property of PKN3.
Both PKN1 and 2 can phosphorylate and thereby regulate
cytoskeletal substrates. Microinjection of a kinase inactive PKN2
led to the disruption of stress fibres in NIH3T3 cells [4] while
kinase inactive forms of PKN1 prevented insulin induced actin
stress fibre break down and membrane ruffling [23]. PKN1
interacts with and phosphorylates the microfilament protein a-
actinin [24] and PKN2 was reported to phosphorylate cortactin
[17]. Cortactin is known to enhance actin polymerization by
activating the Arp2/3 complex and hence contribute to tumour
cell migration and metastasis [25]. PKN1 can also indirectly
influence the contractility of myosin by increasing the inhibitory
effects of CPI-17 on myosin phosphatase [26]. Moreover, PKNs
have been described to regulate intermediate filaments, for
example vimentin glial fibrillary acidic protein as well as
neurofilament proteins ([27,28]). These examples of PKN1 and
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2 as possible players in cytoskeleton dynamics together with data
that PKN1 can act upstream of MAP kinases JNK [29] and p38
[30,31] suggest that PKN1 and 2 may be able to drive cell
migration in addition to PKN3.
PKN3 has been considered the primary player in PKN-dependent
tumour cell invasion [18] with no role for PKN1 or PKN2. Here we
have assessed whether this is reflective of expression, function or
cellular wiring. We have screened 22 tumour cell lines for their PKN
expression signatures. Of these cell lines, we selected 5637 bladder
tumour cells as a model for the enriched expression of PKN2. By
using siRNA knock-down and rescue, we addressed the contribution
of individual PKN isoforms to tumour cell migration and invasion.
Our data argue that anti-invasive therapies would be most effective if
all 3 PKN isoforms were abrogated.
Results
Expression of PKN isoforms in tumour cell lines
In order to study the contribution of individual PKN isoforms to
cell migration we compared 22 tumour cell lines for the relative
expression levels of PKN1, 2 and 3. All cell lines expressed at least
one PKN isoform, with lines displaying considerable variations
(.10-fold) in levels of individual PKNs (Figure 1A). PKN1 was
broadly expressed and consistently evident in breast tumour cells;
it has recently been identified in an amplicon in triple negative
breast cancer [32]. PKN2 protein was also broadly expressed with
high levels in 3/4 bladder cell lines. The expression of PKN3
varied the most among tumour cell lines with for example very
high and very low levels evident in breast tumour cell lines.
Because of the relative enrichment in the expression of PKN2 in
5637 cells we selected these as the model for analysis by knock-
down. In parallel, some studies were also performed in MDA-MB-
468 cells where all three isoforms displayed good relative
expression. Quantitation of absolute expression employing recom-
binant PKN proteins to titre antisera, determined that for 5637
cell PKN1, 2 and 3 were expressed at 1.1, 0.21 and 0.08 mg/mg
cell protein; for MDA-MB-468 cells these values were: 16.7, 0.12
and 0.44 respectively.
In these model systems, all three PKN isoforms were depleted
by siRNA and scratch wound assays were employed to assess
requirements for PKN during migration. As shown in Figure 1B
for 5637 bladder cells, we observed a ,50% reduction in speed of
wound closure in the absence of PKN1/2/3 compared to the
control knock-down cells. The depletion of PKN1/2/3 isoforms in
5637 bladder cells resulted in a significant reduction in the speed
of wound closure on all cell matrices tested, but particularly on
collagen (Figure 1C). In MDA-MB-468 cells migration was also
reduced albeit less robustly and in this model most responsively on
fibronectin (Figure S1).
PKN1 and PKN2 are important for 5637 bladder tumour
cell migration
siRNA against individual PKN isoforms or pairwise combina-
tions thereof were tested in wound healing assays on collagen for
5637 cells. Depletion of either PKN1 or PKN2 had a significant
effect on migration, while depletion of PKN3 had no effect under
any circumstances (Figure 1D). In combination knock-downs for
5637 cells, no greater effect was observed than that of PKN2
knock-down alone and 3/3 PKN2 directed siRNAs were effective
in inhibiting migration. Westerns (Figure 1E) indicate the efficacy
of each siRNA or combination. For PKN3, variation in batches of
purified antibody precluded the routine monitoring of endogenous
PKN3, however the efficacy of the siRNA to PKN3 was
demonstrated employing a GFP-PKN3 fusion (see Figure 1E
lower panel); specificity was evident from the westerns for
endogenous PKN1 and PKN2 (Figure 1E upper panel).
PKN influences speed and direction of movement
To determine the underlying altered property in PKN depleted
5637 cells, we tracked single cell movement during scratch wound
assays. Figure 2 shows examples of scratch wounds immediately
after wounding (top row) and after 6 h (bottom row), when the
untransfected and luciferase transfected controls had closed their
wound almost completely, while PKN2 or PKN1/2/3 knock
down still showed large open areas. The tracks of individually
migrating cells were analysed with Mathematica software and
plotted in speed-time graphs (Figure 2B). Control cells reach a
maximum speed of 102 mm/hr after 3 h of wounding (median
speed 72 mm/hr), while the PKN knock down cells show a rather
flat profile over the entire time of the assay (median speed 42 mm/
hr). The statistical analysis displayed in the box-and-whisker
graphs (Figure 2C) confirms a significant reduction in speed as well
as in the persistence of movement in the PKN knock down cells.
PKN1 and 2 function is necessary for invasion of 5637
bladder tumour cells
It has become clear that cell motility modes and the signalling
pathways activated, differ between movement in 2 versus 3
dimensions (see [33]). Therefore, we analyzed whether PKNs were
also involved in 3D migration/invasion in this model. 5637
bladder tumour cells showed a similar behaviour in the Transwell
migration assay as in the 2D scratch wound assay migrating most
efficiently on collagen coated Transwells. Depletion of PKN2
alone in these cells was sufficient to reduce the number of
migrating cells by 50% (Figure 3), while depletion of PKN1
resulted in only a 25% reduction when compared to Luciferase
knock down cells. As observed in the wound healing assay, in the
combination knock-downs and despite some efficiency variation
associated with use of combined siRNAs, it is evident that the
dominant effect was for PKN2 knock-down.
We next compared 5637 cells for their ability to invade
reconstituted basement membrane in the presence or absence of
individual PKN isoforms using BioCoat Matrigel invasion
chambers. Figure 3C shows images of fixed 5637 cells under
control, PKN1, PKN2 and combined PKN1/2 knock-down
conditions. Depletion of PKN1 reduced the number of invading
cells by 40%, while depletion of PKN2 or both PKN1/2 almost
completely abolished invasion (Figure 3D). Interestingly, knock-
down of all 3 PKN isoforms partially inhibits invasion of MDA-
MB-468 (Figure S2), but depletion of individual PKN isoforms had
no effect (data not shown), indicative of PKN redundancy or
redundant pathways.
To ensure that the reduction in the number of invading cells is
not due to a general defect in 5637 cell proliferation, equal
numbers of cells (56104) were seeded into 12 well plates and kept
in culture until the invasion assay was stopped after 66 h. These
cells together with an aliquot of cells which was taken at the day of
seeding were then processed by western blotting to assess protein
expression and knock-down efficiency at the beginning and at the
end of the invasion assay (Figure 3). The consistent tubulin levels
reflect no effect on division under these conditions, despite the
PKN knock-down.
The PKN2 regulatory domain is required for PKN2
migratory functions in 5637 cells
To define the redundancy of PKNs we rescued PKN2 knock-
down in 5637 cells with different PKN constructs (Figure 4A,B).
PKN and Cell Migration
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An siRNA resistant PKN2 construct (PKN2*) stably reintroduced
into 5637 cells was able to rescue much of the effect of endogenous
PKN2 knock-down in these cells (Figure 4C); 65% inhibition of
migration was reduced to ,20% inhibition on GFP-PKN2*
expression. Rescue with the ectopic expression of an siRNA-
resistant PKN2 confirms the specificity of the observed effects of
PKN2 knock-down. Notably, when GFP-PKN1 was stably
expressed there was no rescue of PKN2 depletion in these cells
Figure 1. Expression of PKN isoforms in tumour cell lines and effect of PKN isoform knock down on wound healing of 5637 cells.
A. Protein concentration of cell lysates were analysed by Bradford and aliquots of 30 mg (lanes 1–17) or 50 mg (lanes 18–22) were separated by SDS-
PAGE and blotted onto Nitrocellulose. Membranes were probed for PKN1, 2 and 3 (lanes 1–22). Tubulin (lane 1–17) or actin (lane 18–22) served as
loading controls. B. 5637 cells were grown in uncoated 24well plates and depleted of PKN1, 2 and 3 by triple siRNA transfection. 72 h post
transfection confluent monolayers were scratched with a pipette tip and wound healing monitored using a lowlight Microscope and analysed by
Metamorph software. siRNA (matched concentration) against Luciferase served as a control. C. 24well plates were coated with 10 mg/ml laminin,
25 mg/ml fibronectin or 50 mg/ml collagen for 1 h at 37uC or overnight at 4uC and blocked with 2% BSA for 30 min at 37uC. 5637 cells were then
seeded onto the coated multiwell plates, PKN expression was knock-down by siRNA transfection and cells were subjected to a wound healing assay
72 h post transfection as in (B). D. 5637 cells grown on 50 mg/ml collagen coated plates, were transfected with PKN isoform specific siRNA. 72 h post
transfection wound healing assays were performed on confluent monolayers. Speed of wound closure of luciferase and PKN knock down cells was
compared using Metamorph software. Cells were then harvested and analysed by western to assess knock down efficiency (lower panels). E. The
expression of PKN1 and PKN2 was monitored by western to determine the extent of knock-down under the conditions indicated. For PKN3, fresh
batches of antisera (as compared to those employed in panel A) would not detect endogenous PKN3 and knock-down by the siRNA directed at this
isoform was confirmed using cDNA expression of a tagged PKN3 (lower panel).
doi:10.1371/journal.pone.0021732.g001
PKN and Cell Migration
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Figure 2. Loss of PKN reduces speed and directionality of 5637 bladder cells during wound healing. 5637 cells grown on collagen
coated plates were transfected with siRNA against luciferase, PKN1, PKN2 or PKN3 as indicated. At 3 days post transfection confluent cell monolayers
were scratched and wound closure filmed with a lowlight microscope. A. Images were taken at the time of wounding (t 0 h) and after 6 h of
migration as indicated. B. Individual cells were picked at random and tracked during migration using AQM-Tracker software. Graphs show the speed
of movement in control and PKN knock down cells over 6 h. The boxed traces represent the length and direction of cell movement of each
individually tracked cell plotted from the same point of origin C. Box and Whisker graphs show the range of speed and persistence of all tracked
control versus PKN knock down cells. The comparison was done using Mathematica software. Stars represent t,0.01 (**) or t,0.5 (*).
doi:10.1371/journal.pone.0021732.g002
PKN and Cell Migration
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(Figure 4D). This suggests non-redundant functions of these
isoforms in migration.
To define further the nature of the non-redundant behaviour,
we employed polyclonal, stable, 5637 cell derivatives, expressing
chimeric constructs comprising various combinations of PKN
isoform regulatory and catalytic domains (Figure 4A,B). Substitu-
tion of the regulatory domain of PKN2 with either that from
PKN1 or PKN3 compromised the ability of the expressed
construct to rescue the effect of PKN2 knock-down (Figure 4E).
By contrast expression of the regulatory domain of PKN2 in
combination with the catalytic domain of PKN1 partially rescued
the effect of PKN2 knock-down. A somewhat variable rescue with
the PKN2/3 chimeric construct was observed despite the good
levels of expression.
Figure 3. Effect of PKN knock down on tumour cell invasion. A. 5637 cells were transfected with siRNA against all PKN isforms either
individually or as a double or triple knock down. 48 h post transfection cells were counted and seeded onto laminin coated Transwell membranes.
Cells were allowed to migrate along a serum gradient for 12 h. Cells were then fixed at the bottom of the filter and counted. B. Western Blot of an
equivalent aliquot of the seeded cells confirms the different efficiencies of PKN knock down. C. 5637 cells were transfected with siRNA against
PKN1or 2 or both. 48 h post transfection cells were counted and then seeded into BD invasion chambers. Invasion was allowed to proceed for 66 h at
37uC. Matrigel was then removed from the inside of the chamber and cells were fixed at the bottom of the chamber and photographed. D. Invading
cells were counted for each condition (panel C) and compared to the number of invading luciferase control cells. E. Equivalent aliquots of PKN
depleted cells as seeded into invasion chambers, were taken for western blots as well as for reseeding into 12 well plates and growth during the
duration of the invasion assay. This allowed a reference point for PKN knock down after 120 h and confirms that the effect of PKN knock down on
invasion is not due to proliferation defects.
doi:10.1371/journal.pone.0021732.g003
PKN and Cell Migration
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Figure 4. Overexpression of full length PKN2 or a PKN2/1 chimera can rescue migration defects of 5637 cells with PKN2 knock
down. A. Scheme of siRNA resistant rescue constructs. B. Comparison of the initial 40 amino acids of the PKNs catalytic domains used for cloning
combinations of PKN regulatory and catalytic domain chimeric constructs. C. 5637 cells were stably transfected with GFP or GFP-PKN2* resistant
PKN and Cell Migration
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Discussion
In view of the heterogeneity of PKN isoform expression, to
dissect the relative potential of isoforms to control migratory
behaviour we screened 22 cell lines for their patterns of PKN
isoform expression to establish a suitable model. All cell lines
express at least one isoform and the relative levels of individual
PKNs showed considerable variation in particular for PKN3. In
the tumour cell line 5637 with relatively enriched expression of
PKN2 compared to other cells tested, we were able to detect a
strong phenotype just by depleting PKN2, with PKN1 depletion
having a weaker effect and PKN3 none at all. The results show
that unlike the situation reported in prostate cancer cells [18],
PKN1 and PKN2 can contribute both to cell migration in wound
healing assays as well as 3D invasion of tumour cells in transwells.
Thus the PKN isoform contribution to cell motility in part reflects
their expression in particular cell systems.
Using the 5637 cell model which is enriched for PKN2
expression, rescue of endogenous PKN2 depletion with the ectopic
expression of an siRNA resistant PKN2 confirmed the specificity
of the observed effects of knock down. Importantly, this phenotype
could not be rescued by simple overexpression of PKN1 or 3.
Since we had concluded that in principle any one of these PKN
isoforms can contribute to migratory behaviour (albeit in other cell
types), this inability to rescue with a heterologous isoform
suggested that specific regulatory inputs might distinguish their
action. To test this, we constructed a series of chimeric PKN
molecules and derived stable cell lines for which we could assess
the migratory behaviour 6endogenous PKN2 knock-down. These
studies indicated that the regulatory domain of PKN2 was critical
for rescue of migration in 5637 cells. Thus, besides full length
PKN2 only the chimera PKN2/1 was able to rescue the migration
defect on PKN2 depletion in these bladder cells; this was despite
the expression of higher levels of other chimeras. The selective
ability of PKN2 to rescue over PKN1, and of the PKN2/1
chimera to rescue compared to others, is indicative of specific
regulatory inputs acting through the PKN2 regulatory domain to
effect its action in migration in this cell model.
The evidence here indicates that although expression patterns
seem to reflect the ability of PKN isoforms to influence migration,
the patterns themselves are overlaid by the exertion of regulatory
inputs that display specificity – in 5637 cells these inputs are
principally PKN2 directed. This heterogeneity of regulation is
consistent with the findings that there are distinct lipid and Rho
family GTPase inputs to this family of kinases. The kinase activity
of PKN1 for example is highly stimulated by phosphatidylinosi-
tol(4,5)bisphosphate, phosphatidylinositol(3,4,5)trisphosphate, ly-
sophosphatidic acid and arachidonic acid [10,12]. PKN2 as well as
PKN3 are less sensitive to arachidonic acid than PKN1 [14,34].
With respect to GTPases, PKN1 was shown to bind Rac and
RhoA [5] where the HR1a motif binds both Rac and RhoA with
high affinity and the HR1b motif binds Rac with much higher
affinity than RhoA [35,36]. PKN1 HR1b is also able to bind
RhoA GDP [5]. PKN2 binds and responds to Rac as does PKN1,
but the regulation of the kinase by Rho GTPases is still
controversial. Quilliam and colleagues [20] found that RhoA
binds PKN2 in a GTP dependent manner, but Vincent and
Settleman reported that PKN2 binds Rho GDP and Rho GTP
with similar kinetics [4]. The extreme C-terminus of PKN2 is also
implicated in Rho GTP binding [37], although this specific amino
acid sequence seems dispensible for our rescue experiments, since
the PKN2/1 chimera will partially rescue. PKN2 and PKN3
contain a proline rich region before the catalytic domain and
binding of adaptor proteins known to interact with PKN2 such as
Nck or Grb4 has been mapped to this proline rich region [20,38].
These interactions are not conserved with PKN1. These
distinctions in upstream regulators are consistent with the
conclusion drawn here that cell-specific regulatory domain inputs
determine PKN action in migration.
The single orthologue of the mammalian PKN proteins has
been shown to be essential for the development of the Drosophila
embryo. Drosophila PKN-/- are embryonic lethal due to defects in
dorsal closure [39], a process which involves migration of the
lateral epidermal flanks and dynamic changes in cell shape to close
a hole in the dorsal epidermis occupied by the amnioserosa. The
dorsal closure process has been linked to migration of epithelial
cells in other organisms and in a similar manner Rho GTPases
have been shown to play an important role [40]. Resonating with
the results described in this paper, Betson & Settlement who
analyzed the ability of PKN mutants to rescue the dorsal closure
defect in Drosophila also found a requirement for the N-terminal
domain of PKN in particular to respond to Rho signalling [41].
Interestingly, the kinase domain of PKN could be replaced by that
of Protein Kinase C53E which is similar to mammalian PKCa
[41]; as observed here, these related AGC kinase domains seem
more interchangeable than their regulatory domains.
Migration of 5637 bladder cells was examined previously by
Koivunen and colleagues, who demonstrated that cell migration of
this epithelial cell line was strongly inhibited by the application of
the conventional PKC inhibitor Go¨6976. This inhibitor caused
translocation of b1 and b4 integrins as well as an increased
number of adherens junctions and desmosomes. Together with the
data from [41] these findings suggest that PKN and PKCa/b
might be linked to the same signalling cascade controlling cell
migration.
Migration of cells can occur through individual cell movement
in a manner often referred to as amoeboid migration or in a more
extended morphology, as well as in a form of collective migration;
different requirements are associated with distinct movement
behaviours [42]. Collective migration provides the active and
passive translocation of mobile and non-mobile cells due to groups
of cells being held together by cell adhesion molecules such as E-
cadherin. Interestingly, PKN2 has been implicated in the
regulation of cell-cell adhesion [43]. Upon Rho stimulation
PKN2 either directly or indirectly activates Fyn tyrosine kinase,
which in turn phosphorylates b-catenin that binds to E-cadherin
against siRNA 2–3. Both cell lines were grown on 20 mg/ml Collagen and transfected with siRNA against PKN2. 3 days post transfection confluent
monolayers were scratched with a pipette tip and wound closure was filmed and analysed using Metamorph software. Cells were then analyzed by
western blot for the efficiency of PKN2 knock down and expression of GFP-constructs shown as a short (top panel) and long (bottom panel) exposure.
D. 5637 stable cell lines expressing GFP or GFP-PKN1 were grown on 20 mg/ml Collagen coated wells, depleted of PKN2 and wounded 3 days post
transfection. Wound Healing was monitored over 8 h and analysed with Metamorph software. Western blot analysis was carried out to assess PKN2
knock down efficiency and overexpression of PKN1. E. Stable 5637 cell lines expressing GFP, GFP-PKN1/2 or GFP-PKN3/2 chimera were depleted of
PKN2 and subject to wound healing assay. Western blot analysis confirms the knock down efficiency of PKN2 and overexpression of GFP-PKN1/2 and
GFP-PKN3/2. F. 5637 cells overexpressing GFP, GFP-PKN2/1 or GFP-PKN2/3 were transfected with siRNA against PKN2. 72 h post transfection cell
monolayers were scratched and wound healing analysed as described above. After 8 h of migration cells were lysed and subject to western blot
analysis to determine knock down efficiency and expression levels of PKN chimeras.
doi:10.1371/journal.pone.0021732.g004
PKN and Cell Migration
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and leads to its translocation to cell-cell contacts and increased cell
adhesion. The bladder tumour 5637 cells migrate in sheets in the
wound assays employed here. It is conceivable that depletion of
PKN2 could cause disturbances in cell-cell adhesion and hence
slow down migration of these cells in wound healing assays. In
adhesion assays of PKN1 and PKN2 depleted cells on different
substrates such as collagen and fibronectin, we found that the
ability and number of cells adhering to these substrates was no
different to luciferase siRNA control cells (data not shown).
However, by using immunoflourescene, we noted that focal
adhesions seemed larger in cells lacking PKN1 or PKN2 than in
control cells (unpublished). Knock-down of the PKN1 downstream
target phospholipase D in HeLa cells, also results in increased focal
adhesions [44]. Furthermore, 5637 cells when stimulated with
proepithelin have been shown to migrate through engagement of a
paxillin, FAK and ERK pathway [45]. PKN1 was shown to bind
the actin bundling protein a-actinin in a phosphatidylinositol
4,5bisphosphate dependent manner [24]. a-actinin helps to shape
dorsal and ventral stress fibers which are anchored with one or
both ends in focal adhesions [46]. Disruption of the PKN-actinin
interaction could result in defective focal adhesions and impair cell
motility. PKN isoforms are also implicated as upstream kinases of
mitogen activated kinases such as p38 ([30,31,47]). It is possible
therefore, that cells depleted of PKN1 and PKN2 have modified
focal adhesions that make them adhere stronger to the substrate
and might result in a delayed detraction of the cell body during cell
migration.
In conclusion, PKN3 is not alone in the PKN family in playing
a role in migration. In 5637 cells PKN2 depletion alone inhibits
2D and 3D migration. As the case grows for PKN isoforms as
targets for intervention in invasive disease, consideration will need
to be given to targeting multiple isoforms in some if not all
situations.
Materials and Methods
Reagents
Collagen (from calf skin), Fibronectin (from bovine plasma),
Laminin (from human placenta) and Fetal Calf Serum were
purchased from Sigma-Aldrich. Transwell inserts with 8 mm pores
were from Corning and BD Biocoat Matrigel Invasion chambers
were obtained from BD Biosciences. PKN1 (also known as PRK1)
and PKN2 (PRK2) antibodies were from BD Transduction
Laboratories, the tubulin antibody was from Sigma-Aldrich and
the actin antibody was from ICN. The GFP antibody was from
CRUK monoclonal antibody services.
Generation of plasmids and site directed mutagenesis
GFP-PKN1 and GFP-PKN2 were as described previously [48].
Polymerase chain reactions were performed using a DNA
Engine DYAD (MJ Research). The reaction mix contained: 1U
Pfu Turbo, 1x Pfu buffer, 0.4 mM ultrapure deoxynucleotide
triphosphate mix (0.4 mM of each dNTP), 5% DMSO, 1 pmol
sense primer, 1 pmol antisense primer and 100 ng DNA template.
Reactions were made up to 50 ml in distilled water. Primary PCR
for PKN regulatory and catalytic domain products, respectively,
were performed with one vector primer. Forward (for) and reverse
(rev) primers were as follows:
EGFP-for: TCACTCTCGGCATGGACGAG or EGFP-rev:
TAAACAAGTTAACAACAACAATTGC and one of the
following cDNA specific primers:
pkn1pkn2_cat for
CGCCCTGTGCAGCCCTCTGAGGAAGTCACAGTTTA-
ATCTACAAGATTTCAGG
pkn1pkn2_reg rev
GGAACTTGAAATCTTCGAGGGTCAGAGGAAACCTT-
TGCTGAGATCTTCTGT
pkn2pkn1_cat for
GAGGACAGAAGATCTCAGCAAAGGTTTCCTCTGAC-
CCTCGAAGATTTC
pkn2pkn1_reg rev
CAACACCTGAAATCTTGTAGATTAAACTGTGACTT-
CCTCAGAGGGCTGC
pkn2pkn3_cat for
GAGGACAGAAGATCTCAGCAAAGGTTTAAACCCCC-
TCGGCTTCAGGA
pkn2pkn3_reg rev
CAACACCTGAAATCTTGTAGATTAAACTGCCTGGT-
GGGGGAGGCTGG
pkn3pkn2_cat for
CCATCTCCACCAGCCTCCCCCACCAGGCAGTTTAA-
TCTACAAGATTTCAGG
pkn3pkn2_reg rev
GCGGAAGTCCTGAAGCCGAGGGGGTTTAAACCTTT-
GCTGAGATCTTCTGT
PKN2*oligo2–3resistent for
CAACGGCACGGAATGTGCCTTTATTTGGAACCACA-
GGGTACT
PKN2*oligo2–3resistent rev
TTCCAAATAAAGGCACATTCCGTGCCGTTGGTTGT-
CTAAAAAATC
Reactions were conducted with a denaturing step at 95uC,
annealing temperature of 62uC and elongation temperature of
72uC for 2 min 20 sec. PCR products were examined by agarose
gel electrophoresis and purified using the QIAquick gel extraction
kit (Qiagen). Specific regulatory and catalytic PCR products were
then pooled to serve as the new template for a second round of
PCR amplification in order to generate the desired PKN full-
length chimaeras using only primers EGFP-for and EGFP-rev.
Reactions were conducted as described above but with an
elongation time of 4 min. The total number of cycles for each
PCR reaction was 25. PCR products were sequenced verified.
Cell culture, transfection and generation of stable cell
lines
MDA-MB-468, MDA-MB-231, MCF7, A549, Calu-1, HI299,
PC3, LNCAP, COLO-741, HT29, COLO320HSR, HEPG2,
HeLa, HT1197, HT1376, UMUC3 and 5637 cells were from
CRUK cell services. 786-0, A-498, Caki-1, SK-HEP-1 and ACHN
transformed human cell lines were obtained from the ATCC. Cells
were seeded in 10 or 15 cm dishes for expression studies by
Western Blotting and in 24well plates for migration assays.
Plasmid transfection was performed with Lipofectamine 2000
(Invitrogen) in Optimem (Life Technologies) according to the
manufacturers instructions.
For the selection of stable polyclonal cell lines expressing GFP-
PKN chimeras, 5637 cells were split 1:4 into DMEM in the
presence of 500 mg/ml G418 (Sigma) at 36 h post transfection.
Resistant cells were then sorted using a FACS sterile sort to
separate GFP-positive cells and these were maintained in culture
in selection medium.
Small interfering RNA
HiPerFect reagent was used to achieve knockdown of PKN
isoforms using targeted siRNA oligos. Complexes were prepared
in DMEM in the absence of serum and oligos targeting PKN
isoforms were used at 5 nM each. An oligo targeting luciferase was
used as a control in all experiments and also to balance the
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concentrations of oligos used so that in all cases the final
concentration of oligo was 15 nM for MDA-MB-468 cells and
10 nM for 5637 cells. All assays were carried out 48–72 hrs post-
transfection. The following target DNA sequences for gene specific
siRNAs (Qiagen) were chosen: LUC control: AATCGAAG-
TATTCCGCGTACG; PKN1a: AAGGGCACGGGAACTG-
GAGTT; PKN1b: AACTGGAGTTGGCTGTGTTCT; PKN1
(cat56): GAAGGTGCTCCTCTCCGAATT; PKN2 (oligo2–3):
AAGCATGGCATGTGTCTCTATT; PKN2 (cat2): GGA-
TATGGAGATAGAACAA; PKN3 (GB3) as described in Leenders
et al 2004: GAGAGCCTGTACTGCGAGAAG; PKN3 (cat3):
CCTGAAGATCGCAGACTTT +
Western blot analysis
Cells were scraped off culture dishes, lysed in RIPA buffer at
4uC and protein concentration was measured by Bradford [49].
Cell lysates with equal concentrations of protein were then
prepared in NuPAGE LDS sample buffer with 0.2 M DTT and
heated at 90uC for 10 mins. Samples were run on precast
NuPAGE 4–12% gels (Invitrogen) with MOPS SDS Running
Buffer containing NuPAGE Antioxidant. RPN800 Full Range
Rainbow Markers (Amersham) were run alongside each set of
samples. Gels were transferred onto polyvinylidene difluoride
membrane (PVDF) or Nitrocellulose membrane (Schleicher &
Schuell) using a wet transfer system (Biorad). Membranes were
blocked by incubation at room temperature for 1 hour in 3% (v/v)
BSA/TBS-T or 5% milk/PBS and then incubated overnight at
4uC in primary antibody diluted 1:1000. Membranes were washed
in TBS-T followed by incubation with the HRP-conjugated
secondary antibodies donkey-anti-mouse (Amersham). Mem-
branes were washed again in TBS-T, developed using enhanced
chemiluminesence (ECL, Amersham) and exposed to Hyperfilm.
For quantitation an ImageQuant LAS 4000 mini instrument was
employed to obtain a series of exposures of the ECL readout and
ImageJ used to determine the quantitation relative to recombinant
PKN proteins.
Migration assays
Scratch wound assays were performed 72 hrs post-transfection
with siRNA oligos on confluent monolayer of cells. A single
vertical wound was made in each well with a Gilson D200 pipette
tip, medium was replaced with DMEM +10% FCS and where
live filming was performed the medium also contained 25 mM
Hepes pH 7.2. Plates were sealed around the edge and a small
hole made in the side to allow a needle to be inserted through
which CO2 was blown. A lowlight microscope with moving stage
and heating box was used to follow the wound closure over
24 hrs. A 5x phase objective was used and an image taken every
15 mins. After the acquisition had finished the cells were
harvested by removing the media, washing once with warm
PBS and then adding 50 ml 2 x LDS sample buffer to each well
and western blots were performed to confirm successful
knockdown of PKN isoforms. The pictures were analysed with
MetaMorph software to calculate the area of each wound at each
time point up to the point of complete closure of the wound.
These values were used to give a speed of migration for each
transfection condition and an average of the replicates (at least
three) was calculated.
For Boyden chamber migration assays, the undersides of
Transwell inserts were coated with either 10 mg/ml laminin,
25 mg/ml fibronectin or 50 mg/ml collagen. These coatings were
performed overnight at 4uC. Membranes were then washed,
blocked in 0.1% BSA for 1 hr at RT, washed again with PBS and
placed into fresh wells of a 24 well plate. 72 hrs post-transfection
with siRNA oligos, cells were harvested by trypsin treatment and
resuspended in DMEM +10%FCS. The number of viable cells for
each sample was counted using a Beckman Coulter Counter. An
equal number of viable cells from each transfection condition were
pelleted by centrifugation at 1000 g for 5 mins and gently
resuspended in DMEM +1% FCS to a final concentration of
46104 cells/ml. 500 ml of DMEM +10%FCS was placed in the
bottom of each well of the plate and 500 ml of cell suspension was
added to the upper chamber of each Transwell insert, another
sample of cells was taken to analyse the efficiency of knockdown by
western blot. The plates were incubated at 37uC, 5% CO2 for
5 hrs (MDA-MB-468) or 8 hrs (5637 cells). Thereafter cells
remaining in the upper chamber of the Transwell insert were
removed by gently cleaning the upper surface of the membrane
with a damp cotton bud and washing once in PBS. Cells on the
lower surface of the Transwell membrane were fixed in 4% PFA.
Cells were permeabilised with 0.1% TritonX-100 in PBS for
10 mins, stained with DAPI (1:10000 dilution) for 5 min and
inserts were washed x 3 with PBS. The extent of cell migration was
calculated by counting the number of cells on the lower surface of
the membrane. This was achieved using a Discovery microscope
by taking nine images of each membrane, which were analysed
using Metamorph software and journals to count the number of
nuclei in each field
Invasion assays
DMEM (0.5 ml 37uC) was added to each BD BioCoat
Growth Factor Reduced MATRIGEL Invasion Chamber and
the matrix was allowed to rehydrate for 2 hrs at 37uC, 5%
CO2. After rehydration 250 ml of the DMEM was carefully
removed and 750 ml of DMEM +10%FCS was placed in the
bottom of each well of the plate. Cells were harvested with
trypsin 48 hrs post-transfection with siRNA oligos and
resuspended in DMEM +10%FCS. The number of viable cells
for each sample was counted using a Beckman Coulter
Counter. An equal number of viable cells from each
transfection condition was pelleted by centrifugation at
1000 g for 5 mins. The cell pellet was gently resuspended in
DMEM +1% FCS to a final concentration of 46104 cells/ml
(MDA-MB-468) or 16105 cells/ml (5637) and 500 ml of cell
suspension were added to the upper chamber of each Boyden
chamber. Samples of cells were also taken to analyse the
efficiency of knockdown by western blot and for seeding into
12 well plates to observe viability of cells. The plates were
incubated at 37uC, 5% CO2 for 24 hrs (MDA-MB-468) or
64 hrs (5637). Thereafter cells and the matrix in the upper
chamber of the Boyden chamber were removed by gently
cleaning the upper surface with a damp cotton bud. The inserts
were processed and the number of cells that had invaded were
counted as for the Boyden chamber migration assays.
Supporting Information
Figure S1 Effect of PKN1- 3 knock down on wound
healing of MDA-MB-468 cells. A. MDA-MB-468 cells were
grown in uncoated 24well plates and depleted of PKN1, 2 and 3
by triple siRNA transfection. 72 h post transfection confluent
monolayers were scratched with a pipette tip and wound healing
monitored using a lowlight Microscope and analysed by
Metamorph software. siRNA (matched concentration) against
Luciferase served as control. B. 24well plates were coated with
10 mg/ml laminin, 25 mg/ml fibronectin or 50 mg/ml collagen
for 1 h at 37uC or overnight at 4uC and blocked with 2% BSA
for 30 min at 37uC. MDA-MB-468 cells were then seeded onto
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the coated multiwell plates, PKN expression was knock-down by
siRNA transfection and cells were subjected to a wound healing
assay 72 h post transfection.
(TIF)
Figure S2 Knock-down of PKN1-3 inhibits invasion of
MDA-MB-468 cells. A. MDA-MB-468 cells were transfected
with siRNA against PKN1/2/3. 48 h post transfection cells were
counted and 20 000 cells were seeded into BD invasion chambers.
Invasion was allowed to proceed for 48 h at 37uC. Matrigel was
then removed from the inside of the chamber and cells were fixed
at the bottom of the chamber and photographed. Invading cells
were counted for each condition and compared to the number of
invading luciferase control cells. B. Equivalent aliquots of PKN
depleted MDA-MB-468 cells as seeded into invasion chambers,
were taken for western blots as illustrated.
(TIF)
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